The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...

When WW launched a new compounded semaglutide product late last year, the stock surged, renewing hopes of growth revival.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.